Zai Lab

China And Asia-Pacific Demographics Will Transform Biopharma Markets

AnalystHighTarget

Not Invested

Consensus Narrative from 12 Analysts

Published

24 Aug 25

Updated

28 Aug 25

AnalystHighTarget's Fair Value

US$75.00

56.6% undervalued

28 Aug

US$32.56

73.6%

-2.8%

73.6%

-2.8%

Author's Valuation

US$75.0

56.6% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$75.0

56.6% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

31.73%

Biotech revenue growth rate

12.30%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.28%

Calculation

US$346.57m

Earnings '28

36.34x

PE Ratio '28

US$12.59b

Market Cap '28

US$12.59b

Market Cap '28

134.70m

No. shares '28

US$93.49

Share Price '28

US$93.49 Share Price '28

Discounted to 2025 @ 7.28% p.a.

US$75.72

Fair Value '25